Inspire Medical Systems, Inc. (INSP) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with reaffirmed revenue guidance, increased EPS guidance, and a focus on growth and profitability. The Q&A section reveals management's confidence in handling potential risks, such as competition and reimbursement changes. The company's strategic focus on expanding the patient pool and maintaining pricing stability, along with the positive outlook for reimbursement updates, supports a positive sentiment. However, some uncertainties remain, such as the impact of competition and physician fee cuts, but overall, the sentiment is positive, suggesting a stock price increase of 2% to 8%.
Key Financial Performance
Fourth Quarter Revenue $269 million, increased 12% year-over-year, primarily driven by growth at existing centers and new center additions.
Full Year Revenue $912 million, increased 14% year-over-year, primarily driven by growth at existing centers and new center additions.
Fourth Quarter Operating Margin Improved year-over-year, primarily due to sales leverage and a higher sales mix of Inspire V systems.
Full Year Operating Margin Improved year-over-year, primarily due to sales leverage and a higher sales mix of Inspire V systems.
Fourth Quarter Net Income Per Diluted Share $4.66, increased $3.51 year-over-year, primarily driven by the release of the company's income tax valuation allowance of net deferred tax assets.
Full Year Net Income Per Diluted Share $4.89, increased $3.09 year-over-year, primarily driven by the release of the company's income tax valuation allowance of net deferred tax assets.
Fourth Quarter Adjusted Net Income Per Diluted Share $1.65, increased $0.51 year-over-year.
Full Year Adjusted Net Income Per Diluted Share $2.42, increased $0.80 year-over-year.
Fourth Quarter Operating Cash Flow $52 million, contributing to a full year total of $117 million.
Full Year Operating Cash Flow $117 million, reflecting strong cash generation.
Share Repurchases $50 million in the fourth quarter, totaling $175 million for the full year.
Cash and Investments $405 million at the end of the quarter, reflecting a strong cash position.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Inspire V system: Demonstrated superiority over Inspire IV with reduced surgical time, improved inspiratory overlap, and a 79.5% responder rate in the Singapore study compared to 66% in the STAR Phase III trial. Transition to Inspire V from Inspire IV is expected later in 2026.
Inspire VI system: Development planned for 2026, featuring sleep detection and auto activation for improved therapy adherence.
3 Tesla MRI compatibility: Recently received FDA approval, enhancing product capabilities.
Revenue growth: Fourth quarter revenue increased by 12% to $269 million, and full-year revenue grew by 14% to $912 million, driven by growth at existing and new centers.
Territory management: 295 U.S. territories and 275 U.S. field clinical representatives, with strategic territory consolidation and increased field clinical reps planned.
Coding challenges: Clarification received for CPT code 64582 with a -52 modifier for Inspire V procedures, potentially reducing professional fees by 10%-50%, impacting physician willingness to perform procedures.
WISeR program: Government initiative affecting Medicare patient procedures in six pilot states, with some denials due to medical criteria inconsistencies and coding issues.
SleepSync enhancements: Testing a prior authorization feature to simplify patient data uploads for prior authorization submissions.
Reimbursement strategy: Short-term focus on minimizing professional fee reductions and achieving consistency across payers. Long-term focus on developing a new CPT code for Inspire V procedures.
Growth strategy: Includes training advanced practice providers, certifying additional surgeons, and driving adoption of SleepSync and digital tools to enhance patient access.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Coding and Reimbursement Challenges: The transition to CPT code 64582 with a -52 modifier for the Inspire V procedure could result in a reduction of professional fees by 10% to 50%, potentially discouraging physicians from performing the procedure and limiting case volumes.
Medicare WISeR Program Impact: The WISeR program has led to denials of Medicare cases in six pilot states due to medical criteria inconsistencies and coding issues, affecting Medicare patient procedures in the first quarter of 2026.
Revenue Uncertainty: The dynamic reimbursement landscape has led to a revised and widened revenue guidance for 2026, reflecting potential impacts of coding changes and physician reimbursement rates.
Physician Willingness to Adopt New Procedures: The significant decrease in professional fees due to the -52 modifier may reduce physicians' willingness to adopt the Inspire V procedure, impacting procedure volumes.
Operational and Strategic Execution Risks: The company faces challenges in transitioning from Inspire IV to Inspire V systems, including ensuring stable product inventory and managing the shift in coding and reimbursement policies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Outlook for 2026: The company revised its full-year revenue outlook for 2026 to be in the range of $950 million to $1 billion, representing 4% to 10% growth. This range reflects the expected impact of coding uncertainty and the adoption of CPT code 64582 with the -52 modifier.
Professional Fee Impact: The low end of the revenue outlook assumes a 50% discount to the physician fee, while the high end assumes a 10% discount. The company expects to gain further insights into the professional fee associated with the modifier in the first half of the year.
Adjusted Operating Margin: The company expects an adjusted operating margin in the range of 6% to 8% for 2026.
Net Income Projections: Net income per diluted share is expected to range from $1.23 to $1.81, while adjusted net income per diluted share is projected to range from $1.85 to $2.35.
Capital Expenditures: Capital expenditures for 2026 are expected to be between $45 million and $50 million.
Quarterly Revenue and Profit Trends: Revenue in the first quarter of 2026 is expected to be approximately flat compared to the prior year due to coding uncertainty. Sequential improvement in revenue and net income is expected throughout the year, with the fourth quarter having the highest levels of revenue and profit.
Product Development: The company plans to focus on the development of Inspire VI, which will include features like sleep detection and auto activation to maximize therapy adherence.
Reimbursement Strategy: The company is working on short-term initiatives to minimize the reduction in professional fees and drive consistency across the country. Long-term plans include developing a new CPT code for the Inspire V procedure.
Inventory and Transition Plans: The company expects stable product inventory for Inspire V throughout 2026 and plans to transition the existing Inspire IV IPG line to Inspire V later in the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: We completed $50 million of share repurchases in the fourth quarter, bringing the full year total to $175 million.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:When do you expect to have more clarity on the physician fee with Gen 5 using the 82 code and the -52 modifier?
A:Timothy Herbert explained that the evolution to the -52 modifier is a process. The company is working proactively with MACs and commercial payers to describe the differences between Inspire IV and Inspire V and to drive consistency. They believe they can achieve alignment with MACs and ensure predictability for implants.
Q:Why not push the Gen 4 system more aggressively given the reimbursement is buttoned up with 64582 until Gen 5 is fully situated?
A:Timothy Herbert stated that they are pursuing a new CPT code as the -52 modifier is not a long-term solution. They believe payers will minimize the reduction in reimbursement for Inspire V procedures. They also have inventory of Inspire IV available for those who wish to continue using it.
Q:What is specific to the revision of the 2026 revenue guidance related to the new reimbursement landscape and the WISeR program?
A:Timothy Herbert explained that the WISeR program caused some disruption in six pilot states due to technical challenges with the portal. However, the primary reason for the revenue reduction is the coding uncertainty and the potential shift to the -52 modifier for the remainder of the year.
Q:What percent of physicians are salary-based versus RVUs, and what feedback are you getting from the field regarding the modifier?
A:Timothy Herbert mentioned that the majority of physicians are in private practice, while those in large medical practices or academic centers tend to be salary-based. Academic centers account for about 30% of implanting surgeons. Feedback from the field indicates efforts to minimize the reimbursement reduction.
Q:How do you get comfort with the 4% to 10% guidance range for the year, especially with the potential 50% cut with the -52 modifier?
A:Timothy Herbert stated that they ran models based on the percentage of surgeons at academic or large facilities versus private practice and the timing of implementation of the -52 modifier. They believe they can work with MACs to minimize the reduction and aim for the higher end of the range.
Q:What is the pathway to getting a new code, and what happens to the physician payment during that process?
A:Timothy Herbert explained that the new code application process involves review by the AMA CPT panel and the RUC process for valuation. In the meantime, they will use 64582 and not a temporary or miscellaneous code. There is a risk that the RUC could identify a lower payment.
Q:How do you plan to grow earnings and expand margins in a slower revenue environment?
A:Timothy Herbert emphasized cost discipline and flexibility in spending. They aim to minimize the reimbursement reduction and achieve the higher end of their revenue range to gain leverage.
Q:Is there any appetite to minimize the impact hospitals will see, and how should we think about device pricing in 2026?
A:Timothy Herbert stated that current pricing aligns well with 64582, and they plan to maintain consistent product pricing. However, pricing is something they can review if needed.
Q:How are you thinking about your installed base of trained accounts and their progression throughout 2025?
A:Timothy Herbert mentioned that they ramped up opening centers in the second half of the year and plan to maintain that rate. New centers are expected to have strong utilization.
Q:What clarification did you receive recently that led to the conclusions provided today?
A:Timothy Herbert stated that they worked with societies and agencies to gain clarity on coding. They now know that 64582 will be the code going forward, including the -52 modifier.
Q:What are you assuming in the guidance regarding the impact of competition?
A:Timothy Herbert acknowledged some impact from competition but expressed confidence in their technology and data. They believe they are in a strong market position.
Q:What are your expectations for commercial payers regarding the transition to 64582 with a modifier?
A:Timothy Herbert explained that commercial payers currently allow 64568, but they expect a transition to 64582 with the -52 modifier over time. They plan to work with payers on global contracts to ensure proper physician reimbursement.
Q:Why is the territory count down by 40 from a year ago, and how does this impact the rep-to-center ratio?
A:Timothy Herbert explained that the reduction was intentional to align with strategic territories and improve utilization. They are adding field clinical reps to support case management and training.
Q:What is the latest on GLP-1s and their impact on the business?
A:Timothy Herbert stated that GLP-1s could be a tailwind as they help high BMI patients lose weight and qualify for Inspire. They are monitoring data to see the percentage of patients whose sleep apnea resolves with GLP-1s.
Q:How are you managing patients who face bottlenecks due to physicians being less willing to perform procedures?
A:Timothy Herbert emphasized the strength of Inspire V and its clinical data. They plan to focus on centers that remain consistent and work with payers to minimize the impact on private practice physicians.
Q:How do you determine the impact of physician fee cuts on the business?
A:Timothy Herbert explained that the impact varies across centers. Academic centers and ASCs with partial owner surgeons are less affected. Private practice physicians are most at risk, and efforts are focused on minimizing the professional fee reduction.
Q:What is the cadence for achieving the high end of the revenue guidance?
A:Timothy Herbert expects acceleration in the second half of the year as they gain clarity on reimbursement and minimize the professional fee reduction.
Q:What is the contribution of OUS (outside the U.S.) revenue in 2026?
A:Ezgi Yagci stated that OUS revenue is expected to contribute 4% to 5% of the total revenue for 2026.
Q:Why not pursue a CPT III code while transitioning to a CPT I code?
A:Timothy Herbert explained that a CPT III code would not provide stable reimbursement and could introduce variability. They chose to stay with a Category I code for long-term clarity and consistency.
Q:What portion of claims have been rejected versus accepted under the new coding guidelines?
A:Timothy Herbert stated that claims have been paid under both 64568 and 64582, with some denials requiring clarification. The situation has been inconsistent, but clarity on coding should improve consistency.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer to questions about the specific details of the clarification received regarding coding and the exact timeline for gaining claims data to determine the impact of the -52 modifier. Additionally, they did not provide a clear breakdown of the impact of competition on their guidance or the specific steps being taken to address physician bottlenecks.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AHI Singapore
AI software
ASC site
Commission report
Form week
Forward statement
Full Conference
Herbert Chairman
III trial
IPG line
IV system
MAC
Medicare case
WISeR program
access therapy
authorization
challenge
clarification
code procedure
coding procedure
criterion
field rep
government
health care
initiative
occurrence
payer
procedure week
product
reduction fee
reimbursement action
responder rate
territory
use modifier
INSP Transcript
Inspire Medical Systems, Inc. (INSP) Q4 2025 Earnings Call Transcript
Positive2-11
The earnings call summary indicates strong financial performance with reaffirmed revenue guidance, increased EPS guidance, and a focus on growth and profitability. The Q&A section reveals management's confidence in handling potential risks, such as competition and reimbursement changes. The company's strategic focus on expanding the patient pool and maintaining pricing stability, along with the positive outlook for reimbursement updates, supports a positive sentiment. However, some uncertainties remain, such as the impact of competition and physician fee cuts, but overall, the sentiment is positive, suggesting a stock price increase of 2% to 8%.
Inspire Medical Systems, Inc. (INSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Inspire Medical Systems, Inc. (INSP) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Neutral12-2
Inspire Medical Systems, Inc. (INSP) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-10
INSP Slides
Inspire Medical Systems Q4 2025 slides: revenue hits $912M, projects slower growth2026-02-11
Inspire Medical Systems Q3 2025 slides: revenue up 10%, EPS beats expectations2025-11-03
Inspire Medical Systems Q2 2025 slides: Revenue growth continues with Inspire V launch2025-08-04
Inspire Medical Systems Q1 2025 slides: Revenue up 23% as Inspire V launch approaches2025-05-05
INSP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
